Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661262 | 0.90 | KDM4E (0.52) | CTSDKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL1661048 | 0.89 | CTSD (0.48) | CTSDKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL1661786 | 0.88 | FAAH (0.47) | CTSDCYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL1661782 | 0.87 | KDM4E (0.43) | CTSDKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL1662968 | 0.87 | ALDH1A1 (0.47) | CTSDKDM4EKDM5CPHF8KDM2A | |
| Tetradecanehydrazide SCHEMBL1661791 | 0.86 | FAAH (0.50) | CTSDCYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL1660802 | 0.86 | FAAH (0.50) | CTSDCYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL1660806 | 0.86 | FAAH (0.50) | CTSDCYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL1660009 | 0.86 | FAAH (0.50) | CTSDCYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL1661778 | 0.86 | FAAH (0.50) | CTSDCYP1A2CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488021-A1 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | Dow AgroSciences LLC (US) | 2012-08-22 | — | — | EP | claimed |
| WO-2011047025-A1 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | DOW AGROSCIENCES LLC (US) | 2011-04-21 | — | — | WO | claimed |
| US-20110086761-A1 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | DOW AGROSCIENCES LLC (US) | 2011-04-14 | — | — | US | claimed |
| EP-2488021-A1 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | Dow AgroSciences LLC (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011047025-A1 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | DOW AGROSCIENCES LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086761-A1 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | DOW AGROSCIENCES LLC (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086761-A1 | COMPOSITIONS AND METHODS TO CONTROL OOMYCETE FUNGAL PATHOGENS | ERG28, DPM1, BROX | CTSD 2183/4885KDM4E 1284/4885KDM5C 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.